Ironwood names Jeffrey Silber chief medical officer, succeeding Michael Shetzline

Ironwood Pharmaceuticals, Inc. Class A

Ironwood Pharmaceuticals, Inc. Class A

IRWD

0.00
  • Ironwood named Jeffrey Silber chief medical officer, head of research and drug development, succeeding retiring CMO Michael Shetzline.
  • Silber starts July 20, 2026; Shetzline will stay on as an advisor during the transition.
  • Silber will oversee research and drug development, regulatory affairs, medical affairs, reporting to CEO Tom McCourt.
  • He joins from Vedanta Biosciences, where he served as chief medical officer since 2020, leading microbiome-based GI therapy development.
  • Earlier roles included senior vice president in clinical development at EMD Serono/Merck KGaA, vice president at AbbVie, leadership posts at Merck.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714515996) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.